Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$4.20
-6.9%
$10.35
$4.13
$93.75
$2.48M-0.0968,173 shs25,757 shs
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$0.01
+0.7%
$0.02
$0.01
$2.50
$855K-1.04800,311 shs87,733 shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$6.80
+0.4%
$6.50
$3.72
$8.69
$86.36M0.833,607 shs3,817 shs
OptiNose, Inc. stock logo
OPTN
OptiNose
$1.05
-8.0%
$1.40
$0.80
$2.10
$118.59M-0.1885,141 shs313,182 shs
Otonomy, Inc. stock logo
OTIC
Otonomy
$0.01
$0.06
$0.01
$2.54
$582K1.54937,525 shsN/A
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-5.65%-0.10%-59.59%-49.89%-94.10%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
+15.83%-7.33%-33.17%-51.84%-99.41%
LifeVantage Co. stock logo
LFVN
LifeVantage
+3.04%+12.65%+9.19%+11.90%+81.99%
OptiNose, Inc. stock logo
OPTN
OptiNose
+12.87%+32.68%-13.64%-10.94%-43.00%
Otonomy, Inc. stock logo
OTIC
Otonomy
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
0.5183 of 5 stars
0.04.00.04.61.10.00.0
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
2.0421 of 5 stars
0.03.01.72.72.61.71.3
OptiNose, Inc. stock logo
OPTN
OptiNose
4.0352 of 5 stars
3.52.00.04.21.92.50.6
Otonomy, Inc. stock logo
OTIC
Otonomy
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
3.00
BuyN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
2.00
HoldN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
N/AN/AN/AN/A
OptiNose, Inc. stock logo
OPTN
OptiNose
3.00
Buy$4.00281.28% Upside
Otonomy, Inc. stock logo
OTIC
Otonomy
N/AN/AN/AN/A

Current Analyst Ratings

Latest EVFM, OTIC, LFVN, ATXI, and OPTN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/29/2024
OptiNose, Inc. stock logo
OPTN
OptiNose
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
3/18/2024
OptiNose, Inc. stock logo
OPTN
OptiNose
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
3/18/2024
OptiNose, Inc. stock logo
OPTN
OptiNose
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$3.00 ➝ $4.00
3/11/2024
OptiNose, Inc. stock logo
OPTN
OptiNose
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$5.00
(Data available from 5/7/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/A$1.92 per shareN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$18.22M0.05$1.40 per share0.01($2.64) per share-0.01
LifeVantage Co. stock logo
LFVN
LifeVantage
$213.40M0.40$0.54 per share12.67$2.71 per share2.51
OptiNose, Inc. stock logo
OPTN
OptiNose
$70.99M1.67N/AN/A($0.77) per share-1.36
Otonomy, Inc. stock logo
OTIC
Otonomy
$130K4.48N/AN/A$0.97 per share0.01

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-$10.38M-$95.49N/AN/AN/AN/A-335.11%5/10/2024 (Estimated)
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
$52.98M-$7.62N/AN/A290.81%-90.20%331.20%N/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.54M$0.2824.29N/A1.75%27.02%12.42%8/26/2024 (Estimated)
OptiNose, Inc. stock logo
OPTN
OptiNose
-$35.48M-$0.32N/AN/AN/A-50.06%N/A-33.05%5/9/2024 (Estimated)
Otonomy, Inc. stock logo
OTIC
Otonomy
-$51.18M-$0.77N/AN/AN/A-137.86%-68.50%N/A

Latest EVFM, OTIC, LFVN, ATXI, and OPTN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/27/2024Q4 2023
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A-$0.44-$0.44-$0.44N/A$4.84 million
3/18/2024Q4 2023
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A$42.00+$42.00$0.56N/AN/A
3/7/202412/31/2023
OptiNose, Inc. stock logo
OPTN
OptiNose
-$0.10-$0.09+$0.01-$0.09$19.90 million$19.87 million      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/AN/A
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.142.06%N/A50.00%1 Years
OptiNose, Inc. stock logo
OPTN
OptiNose
N/AN/AN/AN/AN/A
Otonomy, Inc. stock logo
OTIC
Otonomy
N/AN/AN/AN/AN/A

Latest EVFM, OTIC, LFVN, ATXI, and OPTN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2024
LifeVantage Co. stock logo
LFVN
LifeVantage
Quarterly$0.042.44%5/31/20245/31/20246/14/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A
1.55
1.55
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
N/A
0.13
0.10
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.68
1.01
OptiNose, Inc. stock logo
OPTN
OptiNose
N/A
0.60
0.55
Otonomy, Inc. stock logo
OTIC
Otonomy
N/A
1.74
1.74

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
17.34%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.22%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
OptiNose, Inc. stock logo
OPTN
OptiNose
85.60%
Otonomy, Inc. stock logo
OTIC
Otonomy
41.23%

Insider Ownership

CompanyInsider Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
1.80%
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
0.21%
LifeVantage Co. stock logo
LFVN
LifeVantage
6.76%
OptiNose, Inc. stock logo
OPTN
OptiNose
2.20%
Otonomy, Inc. stock logo
OTIC
Otonomy
1.09%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
3590,000578,000Not Optionable
Evofem Biosciences, Inc. stock logo
EVFM
Evofem Biosciences
3761.06 million60.93 millionNot Optionable
LifeVantage Co. stock logo
LFVN
LifeVantage
24812.70 million11.84 millionOptionable
OptiNose, Inc. stock logo
OPTN
OptiNose
132113.04 million110.55 millionNot Optionable
Otonomy, Inc. stock logo
OTIC
Otonomy
5168.53 million67.78 millionOptionable

EVFM, OTIC, LFVN, ATXI, and OPTN Headlines

SourceHeadline
Top 8 Best Antibiotic for Dog Ear Infection: Top Picks and How to Use Them in 2023Top 8 Best Antibiotic for Dog Ear Infection: Top Picks and How to Use Them in 2023
straight.com - April 21 at 9:08 PM
Allergic Contact Dermatitis and Topical AntibioticsAllergic Contact Dermatitis and Topical Antibiotics
medscape.com - September 10 at 4:13 PM
Hearing Loss in AdultsHearing Loss in Adults
nejm.org - August 21 at 11:30 PM
Research PublicationsResearch Publications
slu.edu - August 4 at 7:44 PM
Management of Pediatric Otitis MediaManagement of Pediatric Otitis Media
medscape.com - May 11 at 11:26 PM
Hearing Loss Pipeline Analysis Demonstrates 35+ Key Companies at the Horizon Expected to Transform the Treatme - openPRHearing Loss Pipeline Analysis Demonstrates 35+ Key Companies at the Horizon Expected to Transform the Treatme - openPR
news.google.com - May 8 at 10:11 AM
Alluvial Capital Management Q1 2023 Letter To Partners - Seeking AlphaAlluvial Capital Management Q1 2023 Letter To Partners - Seeking Alpha
news.google.com - April 28 at 7:44 AM
Vertigo Treatments Market Forecast: Analysis and Insights for 2023 ... - Digital JournalVertigo Treatments Market Forecast: Analysis and Insights for 2023 ... - Digital Journal
news.google.com - April 27 at 9:58 AM
Hearing Loss Clinical Trial Pipeline Insights Featuring 32+ Companies - openPRHearing Loss Clinical Trial Pipeline Insights Featuring 32+ Companies - openPR
news.google.com - April 25 at 4:57 PM
ENT Disorder Treatment Market to grow at a CAGR of over 3.3 ... - Digital JournalENT Disorder Treatment Market to grow at a CAGR of over 3.3 ... - Digital Journal
news.google.com - April 24 at 7:52 AM
Hearing Loss Clinical Trials 2023 (Updates): FDA Approvals ... - Digital JournalHearing Loss Clinical Trials 2023 (Updates): FDA Approvals ... - Digital Journal
news.google.com - April 11 at 10:37 PM
ENT Disorder Treatment Market : Factors Benefitting Emergence of ... - Digital JournalENT Disorder Treatment Market : Factors Benefitting Emergence of ... - Digital Journal
news.google.com - April 10 at 7:51 AM
[Research Report] Hearing Loss Disease Treatment Market Improve ... - Digital Journal[Research Report] Hearing Loss Disease Treatment Market Improve ... - Digital Journal
news.google.com - April 10 at 7:51 AM
Hearing Loss Emerging and Marketed Drugs Assessment (2023 ... - Digital JournalHearing Loss Emerging and Marketed Drugs Assessment (2023 ... - Digital Journal
news.google.com - April 3 at 7:09 PM
Hearing-focused biotech grabs trio of programs from Otonomys fire ... - Endpoints NewsHearing-focused biotech grabs trio of programs from Otonomy's fire ... - Endpoints News
news.google.com - March 30 at 1:22 PM
Alector cuts 11% of workforce as it doubles down on late-stage ... - Endpoints NewsAlector cuts 11% of workforce as it doubles down on late-stage ... - Endpoints News
news.google.com - March 30 at 8:21 AM
Mathai Mammen hands in J&Js R&D keys to lead Greg Verdines ... - Endpoints NewsMathai Mammen hands in J&J's R&D keys to lead Greg Verdine's ... - Endpoints News
news.google.com - March 30 at 8:21 AM
Boehringer reports robust sales led by type 2 diabetes and ... - Endpoints NewsBoehringer reports robust sales led by type 2 diabetes and ... - Endpoints News
news.google.com - March 30 at 8:21 AM
Seelos Therapeutics temporarily stops study in rare neuro disorder ... - Endpoints NewsSeelos Therapeutics 'temporarily' stops study in rare neuro disorder ... - Endpoints News
news.google.com - March 30 at 8:21 AM
Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to ... - PR NewswireSpiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to ... - PR Newswire
news.google.com - March 29 at 8:47 PM
Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear ... - BioSpaceSpiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear ... - BioSpace
news.google.com - March 29 at 10:46 AM
Otic Drug Market Size Historical Growth, Analysis, Opportunities and Forecast To 2029| Pediapharm Novus Therap - openPROtic Drug Market Size Historical Growth, Analysis, Opportunities and Forecast To 2029| Pediapharm Novus Therap - openPR
news.google.com - March 27 at 9:52 AM
Hearing Loss Pipeline Drugs and Companies Insight Report, 2023 ... - Digital JournalHearing Loss Pipeline Drugs and Companies Insight Report, 2023 ... - Digital Journal
news.google.com - March 23 at 9:50 AM
Hearing Loss Disease Treatment Market 2023 key developmental ... - openPRHearing Loss Disease Treatment Market 2023 key developmental ... - openPR
news.google.com - March 22 at 6:46 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Avenue Therapeutics logo

Avenue Therapeutics

NASDAQ:ATXI
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
Evofem Biosciences logo

Evofem Biosciences

NASDAQ:EVFM
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
LifeVantage logo

LifeVantage

NASDAQ:LFVN
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.
OptiNose logo

OptiNose

NASDAQ:OPTN
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Otonomy logo

Otonomy

NASDAQ:OTIC
Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.